PRLog - March 29, 2012 - LONDON -- Pain is the most common reason patients seek medical care, as it affects the quality of life many people experience and has significant sensory and emotional components. Whilst advances have been made in pain management, few significant ones have occurred, making it harder in recent years to get analgesics to market.
Therapeutics- - - 150- x- 150- EB
In the current economic climate, this makes it even more imperative for companies to improve their R&D methods so that drugs being put forward for clinical trials have the best chance of success.
Hear key presentations from industry-leading experts:
• Kevin Lee, Head of Epigenetics Discovery Unit, Epinova (GlaxoSmithKline)
• Chas Bountra, Professor of Translational Medicine, Head, Structural Genomics Centre Oxford University
• Jonathan Stewart, Disease Area Head, Neuroscience, Immunology and Pain, Bristol-Myers Squibb
• Philip Kym, Associate Director II Pain Discovery Research, Abbott
• Mark Bowlby, Neurophysiology and Pain Lead, Merck
• Dave Shelton, Senior Director, Pfizer Global Research & Development
Key reasons to attend:
• Evaluate recent advances in experimental pain models and translational techniques
• Discuss the current topics in CNS clinical trials
• Develop strategies to improve the chance of success for your candidate drugs
•Discover how epigenetics can help in the elucidation of new targets
• Learn about the current targets in pain drug development and their potential for new therapies
• Network with key industry associates and solution providers to share valuable experiences
# # #
About SMi Group
Pain Therapeutics 2012 is just one of the many conferences that are a part of the SMi Group portfolio. The SMi Group is a world leader in business to business information. With nearly two decades in the business, thousands of senior executives from blue chip companies have already benefitted from SMi’s highly targeted conferences, workshops and publications. For more information, visit www.smi-online.co.uk.
For further information, contact:
Tel: +44 (0)207 827 6115